XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 27.23

+3.2%

Jan 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom jones who wrote (3885)	9/24/1997 3:53:00 AM
From: Webhead	of 17367

I think that it's very unlikely that the DSMB will halt the trial early. They would require truely extraordinary and highly statistically significant data to let a completely new product into the market (which we all know may be used 10X as much off label than on meningococcemia). Since we don't know the criteia used for determining effacacy (other than death) it's a little hard to say at what point you would be expected to reach the >95% confidence level. Given that death is relatively infrequent, a small study of 65 kids may just not be enough to generate reliable data. If the DSMB votes to continue the trial I would not see this as anything unusual or casting a poor light on BPI, rather it IS the expected result. If other criteria are also examined (amputations, days in hospital liver function or whatever) it is possible that enough positive results will encourage an early halt of the trial. Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next